Yesterday, Dec. 1, 2015, 72 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $7.28 to $16,663,500.00.

Highlighted Stocks Traded by Insiders:

Stemline Therapeutics (STML) - FREE Research Report

Bergstein Ivan, who is Chief Executive Officer at Stemline Therapeutics, sold 12,235 shares at $8.20 on Dec. 1, 2015. Following this transaction, the Chief Executive Officer owned 1.9 million shares meaning that the stake was reduced by 0.63% with the 12,235-share transaction.

The shares most recently traded at $8.23, up $0.03, or 0.36% since the insider transaction. Historical insider transactions for Stemline Therapeutics go as follows:

  • 4-Week # shares bought: 2,000
  • 4-Week # shares sold: 10,824
  • 12-Week # shares bought: 2,000
  • 12-Week # shares sold: 10,824
  • 24-Week # shares bought: 2,000
  • 24-Week # shares sold: 10,824

The average volume for Stemline Therapeutics has been 73,800 shares per day over the past 30 days. Stemline Therapeutics has a market cap of $150.3 million and is part of the health care sector and drugs industry. Shares are down 52.52% year-to-date as of the close of trading on Tuesday.

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary therapeutics for cancer stem cells and bulk tumors in the United States. Currently, there are 6 analysts who rate Stemline Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on STML - FREE

TheStreet Quant Ratings

rates Stemline Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Stemline Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Dycom Industries (DY) - FREE Research Report

Baxter Thomas G, who is Director at Dycom Industries, sold 15,000 shares at $87.41 on Dec. 1, 2015. Following this transaction, the Director owned 19,562 shares meaning that the stake was reduced by 43.4% with the 15,000-share transaction.

The shares most recently traded at $88.23, up $0.82, or 0.93% since the insider transaction. Historical insider transactions for Dycom Industries go as follows:

  • 4-Week # shares bought: 2,500
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 2,500
  • 12-Week # shares sold: 1,000
  • 24-Week # shares bought: 2,500
  • 24-Week # shares sold: 1,000

The average volume for Dycom Industries has been 710,600 shares per day over the past 30 days. Dycom Industries has a market cap of $2.8 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 153.38% year-to-date as of the close of trading on Tuesday.

Dycom Industries, Inc. provides specialty contracting services in the United States and Canada. The company has a P/E ratio of 32.0. Currently, there are 4 analysts who rate Dycom Industries a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DY - FREE

TheStreet Quant Ratings

rates Dycom Industries as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, impressive record of earnings per share growth, compelling growth in net income and solid stock price performance. We feel its strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full

Dycom Industries Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Koppers Holdings (KOP) - FREE Research Report

Tritch Stephen R, who is Director at Koppers Holdings, sold 6,381 shares at $22.68 on Dec. 1, 2015. Following this transaction, the Director owned 21,892 shares meaning that the stake was reduced by 22.57% with the 6,381-share transaction.

The shares most recently traded at $22.21, down $0.47, or 2.12% since the insider transaction. Historical insider transactions for Koppers Holdings go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 1,800
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 1,800
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 1,800

The average volume for Koppers Holdings has been 245,200 shares per day over the past 30 days. Koppers Holdings has a market cap of $459.2 million and is part of the basic materials sector and chemicals industry. Shares are down 13.74% year-to-date as of the close of trading on Tuesday.

Koppers Holdings Inc. provides carbon compounds, and chemicals and treated wood products and services in the United States and internationally. The company operates through three segments: Carbon Materials and Chemicals, Railroad and Utility Products and Services, and Performance Chemicals. The stock currently has a dividend yield of 5.17%. Currently, there are 2 analysts who rate Koppers Holdings a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KOP - FREE

TheStreet Quant Ratings

rates Koppers Holdings as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and poor profit margins. Get the full

Koppers Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.